Spandidos D A
Anticancer Res. 1985 Sep-Oct;5(5):485-98.
The oncogenes are a set of genes that have been implicated as the basis of cancer. They are the activated forms of proto-oncogenes which are part of the genetic complement of all normal cells. Activation can result from mutations in the global sense i.e. point mutations, nucleotide deletions or insertions, and chromosomal translocations. These mutations induce quantitative or qualitative changes in oncogene expression. Several human oncogenes identified in tumors and established cell lines have been cloned and studied in great detail using gene transfer techniques. Evidence has accumulated supporting the view that a single oncogene can be involved at different stages or steps in a multi-stage carcinogenesis process. Moreover, a single properly activated oncogene can trigger the whole process of malignant conversion of a normal cell. Thus both the one gene--one cancer and the multigene--one cancer hypotheses may be correct. The most frequently activated oncogenes in tumors detected by the NIH3T3 assay belong to the ras family. These ras genes code for a membrane bound protein (ras p21) which has a GTPase activity. The ras p21 encoded by the T24 activated form of the Ha-ras1 oncogene has an impaired GTPase activity. In view of the location of ras p21 and its biological effects it is proposed that the action of p21 is regulated by growth factors through their membrane receptors. Transcriptional enhancers are cis-acting positive regulatory DNA elements present in viral and cellular genomes. Their involvement in the development of certain types of cancer has been strongly suggested from studies with viruses and chromosome translocations. The in vitro construction of genetic hybrids linking viral transcriptional enhancers and cloned human oncogenes, and the subsequent transformation of early passage cells has been helpful in delineating stages in the malignant conversion of normal cells and gaining insights into the mechanism of carcinogenesis. Transforming growth factors (TGFs) are low molecular weight proteins that reversibly induce anchorage independent growth of certain cells such as the NRK cells. At least two types of TGFs, alpha and beta have been identified. Introduction and expression of cloned human Ha-ras genes in mammalian cells trigger TGF release into the medium. This can occur both in stable transformants and in cells shortly after transfection. The latter suggests that TGF release by the transfected cell is the direct result of the oncogene action rather than a consequence of a cellular change during the process of transformation.(ABSTRACT TRUNCATED AT 400 WORDS)
癌基因是一组被认为是癌症基础的基因。它们是原癌基因的激活形式,而原癌基因是所有正常细胞遗传组成的一部分。激活可能源于整体意义上的突变,即点突变、核苷酸缺失或插入以及染色体易位。这些突变会导致癌基因表达的数量或质量变化。在肿瘤和已建立的细胞系中鉴定出的几种人类癌基因已被克隆,并使用基因转移技术进行了详细研究。越来越多的证据支持这样一种观点,即单个癌基因可能参与多阶段致癌过程的不同阶段或步骤。此外,单个适当激活的癌基因可以触发正常细胞的恶性转化全过程。因此,“一个基因——一种癌症”和“多个基因——一种癌症”的假说可能都是正确的。通过NIH3T3检测法在肿瘤中最常被激活的癌基因属于ras家族。这些ras基因编码一种具有GTP酶活性的膜结合蛋白(ras p21)。由Ha-ras1癌基因的T24激活形式编码的ras p21具有受损的GTP酶活性。鉴于ras p21的位置及其生物学效应,有人提出p21的作用是由生长因子通过其膜受体来调节的。转录增强子是存在于病毒和细胞基因组中的顺式作用正调控DNA元件。对病毒和染色体易位的研究强烈表明它们参与了某些类型癌症的发生。将病毒转录增强子与克隆的人类癌基因连接起来进行遗传杂交的体外构建,以及随后对早期传代细胞的转化,有助于描绘正常细胞恶性转化的阶段,并深入了解致癌机制。转化生长因子(TGFs)是低分子量蛋白质,可可逆地诱导某些细胞(如NRK细胞)的锚定非依赖性生长。至少已鉴定出两种类型的TGFs,即α和β。在哺乳动物细胞中导入并表达克隆的人类Ha-ras基因会促使TGF释放到培养基中。这在稳定转化体以及转染后不久的细胞中都会发生。后者表明转染细胞释放TGF是癌基因作用的直接结果,而不是转化过程中细胞变化的后果。(摘要截选至400字)